EZH2 and neoplasm: Thus, repression of key apoptotic‐entry proteins in tumor cells can be expected to rely largely on EZH2 activity and suggests Polycomb complex components as promising therapeutic targets for the majority of OCCC and a significant proportion of OEC.55, 74, 80